疾病进展对Alport综合征足细胞细胞周期的影响
研究利用X连锁Alport综合征小鼠的FUCCI模型,在足细胞中特异性表达细胞周期阶段荧光报告基因,发现随着慢性肾脏病(CKD)进展,体内足细胞处于G1或更晚阶段的比例增加,且G1和G2期足细胞肥大。杂合子女鼠CKD表现较轻,其G1期足细胞比例介于野生型与雄性Alport小鼠之间。蛋白质组学分析显示疾病状态下G0与G1期足细胞在细胞骨架重组和代谢过程上存在差异,体外实验证实受损足细胞可重新进入细胞周期,并在Alport综合征患者中验证了G1期高表达蛋白PDlim2的上调。
要点
- Alport综合征进展中足细胞细胞周期分布改变,G1或更晚阶段比例增加。
- G1和G2期足细胞表现为肥大,杂合子女鼠G1比例介于野生型与雄性之间。
- PDlim2在Alport综合征患者中上调,提示细胞周期调控可能成为治疗靶点。
核心结论
- 在Alport综合征进展性CKD模型中,足细胞细胞周期分布发生改变,提示细胞周期调控策略可能用于治疗以足细胞减少为特征的各种进展性肾小球疾病。
研究设计与样本
- 使用X连锁Alport综合征小鼠的FUCCI模型,该模型在足细胞中特异性表达细胞周期阶段荧光报告基因,并表现出进展性CKD。
主要发现
- 随着CKD发展,体内足细胞处于G1或更晚细胞周期阶段的比例增加。
- G1和G2期足细胞肥大。
- 杂合子女鼠CKD表现较轻,其G1期足细胞比例介于野生型和雄性Alport小鼠之间。
- 疾病状态下G0与G1期足细胞的蛋白质组学分析显示细胞骨架重组和代谢过程存在差异。
- 体外实验证实受损足细胞可重新进入细胞周期,与体内足细胞相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progression of glomerulosclerosis is associated with loss of podocytes with subsequent glomerular tuft instability. It is thought that a diminished number of podocytes may be able to preserve tuft stability through cell hypertrophy associated with cell cycle reentry. At the same time, reentry into the cell cycle risks podocyte detachment if podocytes cross the G1/S checkpoint and undergo abortive cytokinesis. In order to study cell cycle dynamics during chronic kidney disease (CKD) development, we used a FUCCI model (fluorescence ubiquitination-based cell cycle indicator) of mice with X-linked Alport Syndrome. This model exhibits progressive CKD and expresses fluorescent reporters of cell cycle stage exclusively in podocytes. With the development of CKD, an increasing fraction of podocytes in vivo were found to be in G1 or later cell cycle stages. Podocytes in G1 and G2 were hypertrophic. Heterozygous female mice, with milder manifestations of CKD, showed G1 fraction numbers intermediate between wild-type and male Alport mice. Proteomic analysis of podocytes in different cell cycle phases showed differences in cytoskeleton reorganization and metabolic processes between G0 and G1 in disease. Additionally, in vitro experiments confirmed that damaged podocytes reentered the cell cycle comparable to podocytes in vivo. Importantly, we confirmed the upregulation of PDlim2, a highly expressed protein in podocytes in G1, in a patient with Alport Syndrome, confirming our proteomics data in the human setting. Thus, our data showed that in the Alport model of progressive CKD, podocyte cell cycle distribution is altered, suggesting that cell cycle manipulation approaches may have a role in the treatment of various progressive glomerular diseases characterized by podocytopenia.
引用
- Frank CN, Hou X, Petrosyan A, et al. Effect of disease progression on the podocyte cell cycle in Alport Syndrome. Kidney Int. 2021. PMID: 34562503. doi:10.1016/j.kint.2021.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。